Full-Time

Director – Program and Portfolio Management

Septerna

Septerna

51-200 employees

Licenses GPCR discovery platform to pharma

Compensation Overview

$230k - $255k/yr

+ Stock Options + Annual Target Bonus

San Bruno, CA, USA

In Person

Onsite role in South San Francisco, CA; no remote work.

MBA, PharmD, PhD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Risk Management

Get referred to Septerna

See people who can refer or advise you

Requirements
  • Minimum of at least 10-15+ years of experience within the Biotech or Pharma industry; prior experience in project management required, specifically in the clinical development space
  • Demonstrated track record of managing small molecule discovery projects from early research through development candidates and IND/CTA submissions, clinical trial management, and program strategy development
  • Experience with commonly used project management tools, including Smartsheet
  • Ability to execute diverse and novel strategies in a matrix environment; experience managing and influencing complex issues and a variety of key stakeholders
  • Demonstrated skill in driving execution and focusing on deliverables
  • Strong organizational skills, persistent attention to detail, and ability to work independently and collaboratively to manage timelines and priorities
  • Ability to manage complex situations and adapt to changing business needs by prioritizing multiple tasks
  • Strong interpersonal and communication skills. Demonstrated ability to collaborate closely with individual project leads/teams and scientific leadership
  • Desire to work on a small team in a fast-paced environment
Responsibilities
  • Lead program management for one or more development programs from preclinical development through clinical stages
  • Partner with the cross-functional Program Team to define program strategy, conduct scenario planning, and translate strategy into executable plans to achieve program objectives
  • Identify and manage program-level risks, assumptions, and interdependencies; lead mitigation planning and issue resolution
  • Escalate risks and decision points with clear options and recommendations
  • Work with teams to prepare presentations for internal and external meetings (e.g., team presentations, abstracts, posters, management review, Board of Directors meetings)
  • Develop and maintain integrated program plans, including milestones, timelines, budgets, and resource assumptions
  • Monitor progress against plans, identify deviations, and implement mitigation strategies or alternative scenarios
  • Conduct critical path and dependency analyses to proactively identify risks and bottlenecks
  • Ensure clear, consistent, and transparent communication of program status, key risks, and upcoming milestones through minutes, action items and decision tracking
  • Align diverse stakeholders around priorities, decisions, and execution plans in a matrixed environment
  • Contribute to the design, implementation, and continuous improvement of program management processes, tools, and templates
  • Promote best practices in program planning, governance, and execution across the organization
Desired Qualifications
  • Advanced degree relevant to drug discovery/development; Ph.D./ PharmD/MBA preferred

Septerna develops and licenses a platform called Native Complex™ that enables drug discovery on G protein-coupled receptors (GPCRs) outside of cells. The platform reproduces GPCRs with their original structure, function, and dynamics, allowing scientists to design drugs based on GPCR structures and to perform ultra-large-scale screening across the full GPCR target class. This helps unlock GPCR targets that were previously hard to study and could lead to new medicines. The company differentiates itself by offering an industrial-scale, structure-based discovery workflow specifically for GPCRs, paired with a licensing business model for pharmaceutical companies. Its goal is to expand therapeutic options by turning more GPCRs—previously considered undruggable—into viable drug targets and to bring GPCR-targeted medicines to market through licensing and partnerships.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2022

Get referred to Septerna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $26.5 million, driven by Novo Nordisk collaboration.
  • SEP-479 entered Phase 1 in April 2026, with data expected late 2026.
  • Septerna’s cash totaled $522.1 million, funding operations at least into 2029.

What critics are saying

  • Novo Nordisk controls five metabolic programs; Septerna loses downstream economics after development candidate selection.
  • SEP-631 still needs a second-half 2026 Phase 2b start and toxicology completion.
  • If SEP-479 and SEP-631 fail, Septerna becomes a research platform without marketed drugs.

What makes Septerna unique

  • Native Complex Platform reproduces GPCRs natively, targeting previously inaccessible receptors.
  • Septerna’s portfolio spans endocrinology, immunology, and metabolism with oral small molecules.
  • Novo Nordisk validated the platform with a $195 million upfront alliance in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
StockTitan
May 11th, 2026
Septerna (NASDAQ: SEPN) grows Q1 revenue to $26.5M, trims loss.

Septerna (NASDAQ: SEPN) grows Q1 revenue to $26.5M, trims loss. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Septerna reported strong top-line growth for the three months ended March 31, 2026, with revenue of $26.5 million driven by its Novo Nordisk collaboration, compared with $0.2 million a year earlier. Revenue included recognition of upfront, research and milestone consideration under the agreement. Research and development expense rose to $29.5 million and general and administrative expense to $10.3 million, reflecting pipeline expansion and public-company costs. Net loss narrowed to $8.6 million from $21.5 million, helped by collaboration revenue and $5.0 million of interest income. Septerna ended the quarter with $522.1 million in cash, cash equivalents and marketable securities and deferred revenue of $152.0 million, and expects this liquidity to fund operations at least into 2029. The company also initiated a Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, with data anticipated in late 2026 or early 2027. Key figures. Revenue: $26,523 thousand Net loss: $8,637 thousand R&D expense: $29,535 thousand +5 more Key terms. Native Complex Platform(R), G protein-coupled receptor, at-the-market offering, deferred revenue, +2 more Earnings snapshot. Revenue: $26,523 thousand 05/11/2026 - 01:08 PM Faq. How much revenue did Septerna (SEPN) report for Q1 2026? Septerna reported Q1 2026 revenue of $26.5 million, up from $0.2 million in Q1 2025. This increase primarily reflects recognition of upfront, research and milestone consideration from its Novo Nordisk collaboration under long-term licensing and research agreements. What was Septerna's net loss for the three months ended March 31, 2026? Septerna recorded a Q1 2026 net loss of $8.6 million, narrowing from $21.5 million a year earlier. Higher collaboration revenue and $5.0 million of interest income offset increased research and development and general and administrative expenses tied to pipeline growth. What is Septerna's cash and investment position as of March 31, 2026? As of March 31, 2026, Septerna held $522.1 million in cash, cash equivalents and marketable securities. Management believes this balance will fund planned operating and capital needs at least into 2029, supporting ongoing research, clinical development and public-company obligations. How significant is Septerna's Novo Nordisk collaboration to its Q1 2026 results? The Novo Nordisk collaboration was central to Q1 2026 results, contributing $26.5 million of revenue. This included recognition of a portion of the $195.0 million upfront payment, research services and milestones, with $219.1 million of transaction price still unrecognized for future periods. What clinical progress did Septerna (SEPN) report for SEP-479? Septerna announced first dosing in a Phase 1 trial of SEP-479, its oral PTH1R agonist for hypoparathyroidism. The randomized single- and multiple-ascending dose study in up to 150 healthy adults assesses safety, tolerability, pharmacokinetics and pharmacodynamics, with initial data expected late 2026 or early 2027. How are Septerna's research and development expenses trending? Research and development expenses rose to $29.5 million in Q1 2026 from $19.3 million in Q1 2025. The increase reflects higher employee-related costs, external program spending across the pipeline, and platform investments as the company advances multiple GPCR-targeted oral small molecule programs.

StockTitan
Apr 13th, 2026
Septerna (nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism.

Septerna (nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Septerna, Inc. has begun a Phase 1 clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism. The randomized, placebo-controlled study in healthy adults includes single-ascending and multiple-ascending dose cohorts, with enrollment of up to approximately 150 participants in Australia. The trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics, including effects on endogenous parathyroid hormone and serum calcium, and includes a crossover food-effect study. Septerna anticipates reporting SAD/MAD data in late 2026 or early 2027. SEP-479 aims to offer once-daily oral PTH replacement based on supportive preclinical data. Insights. Septerna advances SEP-479 into Phase 1, adding a new clinical catalyst while keeping risk at an early stage. Septerna has dosed first participants in a Phase 1 study of SEP-479, an oral PTH1R agonist for hypoparathyroidism, with up to 150 healthy volunteers in single- and multiple-ascending dose cohorts plus a food-effect arm. This moves the asset from preclinical into human testing. The company highlights robust preclinical data, including normalization of serum calcium in animal models and a safety profile where hypercalcemia was the main dose-limiting effect. However, all efficacy and tolerability expectations in patients remain unproven until later-stage trials, and Phase 1 outcomes can diverge from preclinical findings. Management guides to SAD/MAD readouts in late 2026 or early 2027, creating a medium-term data catalyst. Alongside this, the broader pipeline and the Novo Nordisk collaboration, which included a $195M upfront payment and potential future milestones, underscore a multi-asset strategy that may help diversify single-program risk. 8-K event classification. 2 items: 7.01, 9.01 Key figures. Planned Phase 1 enrollment: up to ~150 subjects SEP-479 data timing: late 2026 or early 2027 Novo Nordisk upfront payment: $195M +5 more Key terms. Phase 1 clinical trial, single-ascending dose (SAD), multiple-ascending dose (MAD), hypoparathyroidism, +2 more 04/13/2026 - 08:30 AM Faq. What did Septerna (SEPN) announce about SEP-479 in this 8-K? Septerna announced dosing of the first participants in a Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist for hypoparathyroidism. The study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult volunteers using single- and multiple-ascending dose designs. When does Septerna (SEPN) expect Phase 1 data for SEP-479? Septerna anticipates Phase 1 SAD/MAD clinical data for SEP-479 in late 2026 or early 2027. The trial assesses safety, tolerability, and biomarker responses, including serum calcium and endogenous parathyroid hormone, to guide potential dosing strategies for future hypoparathyroidism patient studies. How is Septerna's SEP-479 Phase 1 trial designed? The Phase 1 trial is randomized, placebo-controlled, and includes single-ascending dose and multiple-ascending dose cohorts in healthy adults, plus a crossover food-effect study. Up to about 150 subjects in Australia will be evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics, including calcium-related biomarkers. What unmet need is Septerna (SEPN) targeting with SEP-479? SEP-479 targets hypoparathyroidism, a disease marked by low parathyroid hormone and low blood calcium, causing cramps, fatigue, cognitive issues, and serious complications. Current care relies on frequent calcium and vitamin D dosing or daily PTH injections, leaving demand for more convenient PTH-replacement options. What other key programs does Septerna (SEPN) highlight in its presentation? Septerna highlights SEP-631, an oral MRGPRX2 negative allosteric modulator advancing toward a planned Phase 2b chronic spontaneous urticaria study in the second half of 2026, a TSHR program for Graves' disease and thyroid eye disease, and multiple metabolic programs in collaboration with Novo Nordisk targeting obesity and cardiometabolic diseases. How is Septerna (SEPN) funded for its pipeline plans? Septerna states it is well-capitalized, with cash runway expected to support operating plans at least into 2029. The company also received a $195M upfront payment from Novo Nordisk in July 2025 and is eligible for up to about $500M in potential milestones per collaboration program. Filing exhibits & attachments. 5 documents Press releases.

Associated Press
Mar 9th, 2026
Septerna reports positive Phase 1 data for SEP-631 with Phase 2b trial planned for second half 2026

Septerna, a clinical-stage biotechnology company focused on G protein-coupled receptor drug discovery, has reported positive Phase 1 results for SEP-631, its oral small molecule for mast cell diseases, and announced plans to initiate a Phase 2b trial in chronic spontaneous urticaria in the second half of 2026. The company's SEP-631 demonstrated favourable safety, convenient once-daily dosing and robust suppression of wheal formation in healthy volunteers. Septerna is also advancing SEP-479 towards Phase 1 initiation in the first half of 2026 for hypoparathyroidism. Cash, cash equivalents and marketable securities totalled $548.7 million as of 31 December 2025. The company expects its cash runway to support operations at least into 2029. Full-year 2025 revenue reached $46.0 million, compared to $1.1 million in 2024, driven by collaboration payments from Novo Nordisk.

GlobeNewswire
Jan 8th, 2026
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

Septerna expands leadership with appointment of industry veteran Mark A. Wilson as Chief Legal Officer. January 08, 2026 16:05 ET | Source: Septerna, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) - Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. "We are thrilled to welcome Mark to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His deep expertise across intellectual property strategy and corporate legal matters will be instrumental as we continue to strengthen our governance framework and maximize the value of our portfolio and proprietary Native Complex Platform(TM). Mark's leadership will be vital as we scale the capabilities needed to execute on our long-term strategy and deliver new medicines for patients." "Septerna represents an extraordinary opportunity to be part of a company that is transforming GPCR drug discovery," said Mr. Wilson. "I am excited to join this talented team and contribute to the advancement of innovative therapies that have the potential to make a meaningful difference for patients." Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company's executive committee. During his tenure, Mr. Wilson served as lead attorney for several significant global development and commercialization collaborations, strategic corporate transactions and alternative financings, and he was responsible for the company's global patent strategy. He joined Nektar in 2002 as Patent Counsel and held roles of increasing responsibility, including Vice President of Intellectual Property and General Counsel. Earlier in his career, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California. About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company's proprietary Native Complex Platform(TM) is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

StockTitan
Sep 29th, 2025
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) - Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors.